adarx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $352.5MM
ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/09/2023 | Series C | $200MM | $xx.xx | $827.77MM | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
24,038,463
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management
|
||||||
01/20/2023 | Series B-1 | $46MM | $xx.xx | $484.32MM | Ascenta Capital, OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, Sirona Capital | |
Price per Share
$xx.xx
Shares Outstanding
6,913,353
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ascenta Capital, OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, Sirona Capital
|
||||||
09/08/2021 | Series B | $75MM | $xx.xx | $361.97MM | SR One Capital Management, OrbiMed Advisors, Sirona Capital, Lilly Asia Ventures | |
Price per Share
$xx.xx
Shares Outstanding
14,653,302
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
SR One Capital Management, OrbiMed Advisors, Sirona Capital, Lilly Asia Ventures
|
||||||
05/14/2021 | Series A | $31.5MM | $xx.xx | $52.5MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
31,315,236
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|